# ViraTherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/viratherapeutics

- Industry: Biotechnology
- Headquarters: Innsbruck, Austria
- Website: www.viratherapeutics.com
- Total disclosed funding: $4M
- Latest round: Series A (Jun 24, 2015)
- Investors on record: 3

## About

ViraTherapeutics GmbH is a biotechnology company focused on developing innovative immunotherapy drugs that utilize oncolytic viruses to specifically target and destroy cancer cells, aiming to improve cancer treatment efficacy.Founded in 2013 and headquartered in Innsbruck, Austria, ViraTherapeutics GmbH operates in the biotechnology sector, concentrating on the development of immunotherapy solutions. The company has not undergone any known structural changes since its inception. ViraTherapeutics was acquired by Boehringer Ingelheim International GmbH in September 2018 for EUR 210 million. The CEO of the company is Knut Elbers, who has a history of operational leadership in the biotechnology field. ViraTherapeutics has successfully completed 2 deals to date, with the most recent deal occurring on September 13, 2018, which was a Trade Sale, totaling EUR 210 million.ViraTherapeutics GmbH specializes in the development of innovative immunotherapy drugs utilizing a patented modified version of the Vesicular Stomatitis Virus (VSV-GP). These therapeutic agents are engineered to selectively target and destroy cancer cells while sparing healthy tissue. ViraTherapeutics is currently engaged in preclinical safety and efficacy studies, with plans to initiate clinical trials targeting various cancer types. The primary end users of their products include oncologists and healthcare providers specializing in cancer treatment, focusing mainly on markets in Europe and North America.The revenue model of ViraTherapeutics is centered around partnerships and collaborations with research institutions and pharmaceutical companies interested in developing and commercializing innovative cancer therapies. These collaborations typically involve milestone payments associated with the progression of clinical trials, as well as licensing agreements for their proprietary technologies. The company's EBITDA for the most recent year, 2023, amounts to EUR 3,681,676.40.ViraTherapeutics plans to leverage its recent acquisition by Boehringer Ingelheim to enhance its development capabilities and accelerate the launch of new immunotherapy products. The company is focused on expanding its clinical trials for various cancer types with a targeted launch timeline in the coming years. The recent funding will support the initiation of these trials and facilitate entry into new markets, particularly in North America, scheduled for early 2024.

## Funding rounds

- Series A, Jun 24, 2015, $4M — EMBL Ventures, Boehringer Ingelheim Venture, aws Austria Wirtschaftsservice Gesellschaft

## Investors

- EMBL Ventures (https://capitalatlas.ai/funds/embl-ventures) — Series A
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A
- aws Austria Wirtschaftsservice Gesellschaft — Series A